New cocktail of drugs takes on Hard-to-Treat lung cancer

NCT ID NCT07414953

Not yet recruiting Disease control Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing a new oral drug called HS-10504 combined with several other drugs given by IV in people with advanced non-small cell lung cancer that has worsened after previous treatment. The study will enroll about 400 participants and aims to find safe doses and check whether the combinations shrink tumors. It is not yet recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HS-10504 (oral drug) combined with other drugs (SHR-A2009, HS-20122, HS-20117, SHR-1826, SHR-A2102) given by IV
What this could lead to: If successful, this could point toward a new combination treatment for advanced lung cancer that has stopped responding to prior therapy.
What could go wrong: This is a very early (Phase 1) trial focused on safety and dosing, not yet on effectiveness. The combinations may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG CANCER

More trials for these conditions

Other studies related to the condition(s) this trial covers.